1. Acute invasive fungal rhinosinusitis in post-COVID-19 patients in Vietnam.
- Author
-
Quang LX, Tam TT, Dang LH, Chen YC, Hung SH, Tai TT, Le Vu Hoang N, and Thanh NV
- Subjects
- Humans, Retrospective Studies, Vietnam, Pandemics, Acute Disease, Antifungal Agents therapeutic use, Rhinosinusitis, Rhinitis epidemiology, Rhinitis therapy, COVID-19 complications, Sinusitis epidemiology, Sinusitis microbiology, Meningitis drug therapy
- Abstract
Background: Acute invasive fungal rhinosinusitis (AIFR) is a potentially lethal infection commonly found in immunocompromised patients. It is considered the most aggressive subtype of fungal sinusitis and can lead to severe morbidity and mortality. There was a significant increase in the incidence of AIFR in post-COVID-19 patients compared to AIFR cases before the COVID-19 pandemic. This study aimed to describe the clinical presentation of AIFR associated with COVID-19 illness., Methods: A retrospective study included 22 patients diagnosed with AIFR with a recent COVID-19 infection., Results: The most frequent disease associated with AIFR was diabetes mellitus (95.5%). The mycological analysis identified infection caused by Aspergillus species in 72.7% of patients. Along with stabilizing hemodynamic parameters and controlling any comorbidities, all patients in the present study underwent combined surgical debridement followed by antifungal medications. The overall survival rate was 72.7%. The chance of developing a fatal outcome was significantly higher if meningitis presented initially (odds ratio 35.63, p < 0.05)., Conclusion: The presence of meningitis upon initial diagnosis is related to a significantly higher chance of developing a fatal outcome and should be considered, especially in AIFR patients previously treated for COVID-19 infections. Early diagnosis, early use of antifungal agents, aggressive surgical debridement, and control of comorbid conditions remain crucial in managing AIFR., Competing Interests: Declaration of competing interest All authors declare that there is no conflict of interest associated with this study., (Copyright © 2023 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF